Brean Downgrades United Therapeutics (UTHR) to Hold, Says Price Target Acheived

February 26, 2013 1:10 PM EST
Get Alerts UTHR Hot Sheet
Price: $150.22 --0%

Rating Summary:
    9 Buy, 12 Hold, 3 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade UTHR Now!
Join SI Premium – FREE
Brean Capital downgraded United Therapeutics Corp. (NASDAQ: UTHR) from Buy to Hold.

"We are downgrading United to Hold from Buy due to the achievement of our target price and our view that the next catalyst, a second FDA action on a refiled oral treprostinil application, will result in a second rejection. The resubmission of the oral treprostinil application was accepted, and it was not based on new data, but on the interpretation of existing data after an end-of-review meeting with the FDA. We also view United to have too few significant clinical or regulatory catalysts in the intermediate term after the upcoming FDA response to oral treprostinil," said analyst Jonathan Aschoff.

For an analyst ratings summary and ratings history on United Therapeutics Corp. (NASDAQ: UTHR)click here. For more ratings news on United Therapeutics Corp. click here.

Shares of United Therapeutics Corp. closed at $57.66 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Downgrades

Add Your Comment